documents: FDA-2015-N-1355-0020
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | agency_id | docket_id | title | document_type | subtype | posted_date | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2015-N-1355-0020 | FDA | FDA-2015-N-1355 | Exhibit A Guidance for FDA Staff and Industry Marketed Unapproved Drugs Compliance Policy Guide Sec. 440.100 Marketed New Drugs Without Approved NDAs or ANDAs Sept 9, 2011 re: Comment from Keller and Heckman LLP (Cetylite Industries, Inc.) | Supporting & Related Material | Background Material | 2016-12-27T05:00:00Z | 2016 | 12 | 2016-12-27T19:41:10Z | 0 | 0 | 09000064824380e9 |
Links from other tables
- 0 rows from regs_document_id in fr_regs_crossref